Seelos therapeutics announces data demonstrating statistically significant downregulation of mrna and reduction of alpha synuclein in an in vitro gene therapy study of sls-004 utilizing crispr-dcas9 in dementia with lewy bodies

- a single dose of sls-004 produced 19% downregulation of mrna and ~40% reduction of alpha-synuclein compared to the control group - these results support advancing sls-004 into additional preclinical studies in dementia with lewy bodies new york , june 9, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p
SEEL Ratings Summary
SEEL Quant Ranking